CRDF icon

Cardiff Oncology

3.02 USD
-0.12
3.82%
Updated Apr 1, 2:45 PM EDT
1 day
-3.82%
5 days
-20.53%
1 month
-20.94%
3 months
-29.11%
6 months
22.27%
Year to date
-29.11%
1 year
-47.29%
5 years
243.18%
10 years
-99.38%
0
Funds holding %
of 7,398 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

1,133% more first-time investments, than exits

New positions opened: 37 | Existing positions closed: 3

257% more capital invested

Capital invested by funds: $34.1M [Q3] → $122M (+$87.7M) [Q4]

253% more call options, than puts

Call options by funds: $4.64M | Put options by funds: $1.32M

124% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 17

40% more funds holding

Funds holding: 83 [Q3] → 116 (+33) [Q4]

14.75% more ownership

Funds ownership: 27.45% [Q3] → 42.2% (+14.75%) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$17
463%
upside
Avg. target
$17
463%
upside
High target
$17
463%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Robert Burns
18% 1-year accuracy
31 / 170 met price target
463%upside
$17
Buy
Maintained
28 Feb 2025

Financial journalist opinion

Positive
Zacks Investment Research
4 weeks ago
All You Need to Know About Cardiff Oncology (CRDF) Rating Upgrade to Buy
Cardiff Oncology (CRDF) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
All You Need to Know About Cardiff Oncology (CRDF) Rating Upgrade to Buy
Neutral
Seeking Alpha
1 month ago
Cardiff Oncology, Inc. (CRDF) Q4 2024 Earnings Call Transcript
Cardiff Oncology, Inc. (NASDAQ:CRDF ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Kiki Patel - Investor Relations, Gilmartin Group Mark Erlander - Chief Executive Officer Jamie Levine - Chief Financial Officer Conference Call Participants Joe Catanzaro - Piper Sandler Andy Hsieh - William Blair Robert Burns - H.C. Wainwright Albert Lowe - Craig-Hallum Operator Welcome to the Cardiff Oncology Fourth Quarter 2024 Financial Results and Business Update Conference Call.
Cardiff Oncology, Inc. (CRDF) Q4 2024 Earnings Call Transcript
Negative
Zacks Investment Research
1 month ago
Cardiff Oncology (CRDF) Reports Q4 Loss, Tops Revenue Estimates
Cardiff Oncology (CRDF) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.21 per share a year ago.
Cardiff Oncology (CRDF) Reports Q4 Loss, Tops Revenue Estimates
Neutral
GlobeNewsWire
1 month ago
Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update
- Robust initial efficacy signal with onvansertib + chemo/bev in ongoing first-line RAS-mut metastatic colorectal cancer (“mCRC”) clinical trial (CRDF-004) -
Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update
Neutral
GlobeNewsWire
1 month ago
Cardiff Oncology to Present at Upcoming Investor Conferences
SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present at two upcoming investor conferences. Details of the presentations can be found below.
Cardiff Oncology to Present at Upcoming Investor Conferences
Neutral
GlobeNewsWire
1 month ago
Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update
- Management will hold a conference call on Thursday, February 27 at 4:30 p.m. ET/1:30 p.m. PT - - Management will hold a conference call on Thursday, February 27 at 4:30 p.m. ET/1:30 p.m. PT -
Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update
Positive
Seeking Alpha
1 month ago
Cardiff Oncology: Pioneering RAS-Mutated Cancer Therapies With Onvansertib
Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated cancers, especially mCRC, with a strong therapeutic profile and potential for high returns if approved. Onvansertib's Phase II results indicate superior efficacy in first-line treatment, supporting Cardiff's financial stability and long-term investment potential. The competitive landscape includes therapies like LUMAKRAS and KRAZATI, but Onvansertib's mutation-agnostic approach offers a unique advantage.
Cardiff Oncology: Pioneering RAS-Mutated Cancer Therapies With Onvansertib
Positive
Seeking Alpha
3 months ago
Undercovered Dozen: Ubiquiti, Ready Capital, Cardiff Oncology, Vodafone +
The 'Undercovered' Dozen series highlights lesser-covered stocks, offering fresh investment ideas and sparking community discussions on their potential. Ubiquiti Inc. shows promise with operational improvements, Ready Capital Corporation faces liquidity risks, and TORM plc is crucial despite energy sector volatility. Esperion Therapeutics' breakout and Cardiff Oncology's promising trial data present compelling buy opportunities, while Advantest Corporation's high valuation suggests caution.
Undercovered Dozen: Ubiquiti, Ready Capital, Cardiff Oncology, Vodafone +
Positive
Seeking Alpha
3 months ago
Cardiff Oncology: The Long-Awaited First-Line MCRC Data Are Here, But The Work Is Just Beginning
Cardiff Oncology's phase 2 trial of onvansertib in mCRC shows promising preliminary data, with improved response rates in a dose-dependent manner. Onvansertib appears well tolerated and effective when combined with standard chemotherapy and bevacizumab, but patient numbers remain low, necessitating further validation. Financially, CRDF's equity raise extends their cash runway, supporting the continued development and reducing immediate financial risk.
Cardiff Oncology: The Long-Awaited First-Line MCRC Data Are Here, But The Work Is Just Beginning
Positive
Zacks Investment Research
3 months ago
CRDF Stock Soars on Robust Efficacy Data From Colorectal Cancer Study
Cardiff Oncology stock rallies as initial data from a phase II study of onvansertib shows superior efficacy over SOC chemotherapy in colorectal cancer patients.
CRDF Stock Soars on Robust Efficacy Data From Colorectal Cancer Study
Charts implemented using Lightweight Charts™